AbbVie EVP logs tax-withholding share disposition

AbbVie Inc. executive Roopal Thakkar reported a tax-related share disposition.

Rhea-AI Filing Summary

AbbVie Inc. executive Roopal Thakkar reported a tax-related share disposition. On February 27, 2026, 8,037 shares of AbbVie common stock were disposed of at $232.08 per share to cover tax obligations, leaving 52,376 directly held shares. The filing also reports 2,998 shares held indirectly through a profit sharing trust, reflecting the balance in the AbbVie Savings program as of February 20, 2026, including dividend reinvestment shares that were previously omitted from an earlier Form 3.

Insider Trade Summary

Exercise Price or Tax Liability: 8,037 shares

Exercise Price or Tax Liability 2 txns

Insider Thakkar Roopal

Role EVP, R&D and CSO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock, $0.01 par value	8,037	$232.08	$1.87M
holding	Common Stock, $0.01 par value	--	--	--

Holdings After Transaction: Common Stock, $0.01 par value — 52,376 shares (Direct); Common Stock, $0.01 par value — 2,998 shares (Indirect, Profit sharing trust)

Footnotes (1)

1. F1. Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature. This was inadvertently omitted from the Form 3 filed on December 22, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AbbVie (ABBV) report for Roopal Thakkar?

AbbVie reported that EVP, R&D and CSO Roopal Thakkar disposed of 8,037 shares of common stock on February 27, 2026 to satisfy tax obligations, at a reported price of $232.08 per share, as part of a tax-withholding disposition rather than an open-market sale.

How many AbbVie (ABBV) shares does Roopal Thakkar hold after the Form 4 filing?

After the reported tax-withholding disposition, Roopal Thakkar holds 52,376 AbbVie common shares directly. The filing also shows 2,998 shares held indirectly in a profit sharing trust associated with the AbbVie Savings program, reflecting balances including dividend reinvestments.

Was the AbbVie (ABBV) insider transaction an open-market sale?

No, the transaction was coded as “F,” indicating a tax-withholding disposition. Shares were delivered to cover tax liabilities associated with equity compensation, rather than being sold in a traditional open-market transaction on an exchange.

What is the significance of the AbbVie (ABBV) profit sharing trust holdings?

The Form 4 notes 2,998 AbbVie shares held indirectly in a profit sharing trust, representing the balance in the AbbVie Savings program as of February 20, 2026, including shares acquired via dividend reinvestment that were inadvertently omitted from a prior Form 3.

What price per share was used in Roopal Thakkar’s AbbVie (ABBV) tax-withholding transaction?

The filing reports a transaction price of $232.08 per AbbVie common share for the 8,037 shares disposed of on February 27, 2026, as part of satisfying tax liabilities tied to equity compensation awards.

Did AbbVie (ABBV) correct any prior reporting related to Roopal Thakkar’s holdings?

Yes. The Form 4 explains that the 2,998 shares in the AbbVie Savings program, including dividend reinvestment shares, were inadvertently omitted from Roopal Thakkar’s Form 3 filed on December 22, 2023, and are now reflected as indirect holdings through a profit sharing trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:14 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thakkar Roopal

(Last) (First) (Middle)

1 NORTH WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, R&D and CSO

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	02/27/2026		F		8,037	D	$232.08	52,376	D
Common Stock, $0.01 par value								2,998(1)	I	Profit sharing trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature. This was inadvertently omitted from the Form 3 filed on December 22, 2023.

	/s/ T.O. Odutayo, Attorney-in-Fact for Roopal Thakkar	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.